BRIEF-Amgen Says Aimovig & Amjevita To Be Available At Discounted Monthly Price Of $299 Under Deal With U.S. Govt

Amgen Inc. -1.51% Post

Amgen Inc.

AMGN

347.94

347.94

-1.51%

0.00% Post

Dec 19 (Reuters) - Amgen Inc AMGN.O:

  • AMGEN TAKES ACTION WITH THE U.S. GOVERNMENT TO LOWER THE COST OF MEDICINES FOR AMERICAN PATIENTS

  • AMGEN INC - INVESTED OVER $40 BILLION IN MANUFACTURING AND RESEARCH AND DEVELOPMENT SINCE 2018

  • AMGEN INC - EXPAND ITS DIRECT-TO-PATIENT PROGRAM, AMGENNOW™ TO INCLUDE AIMOVIG(®) (ERENUMAB-AOOE) AND AMJEVITA(®) (ADALIMUMAB-ATTO)

  • AMGEN INC: ALL THREE MEDICINES WILL ALSO BE OFFERED THROUGH TRUMPRX.GOV.

  • AMGEN INC: AIMOVIG & AMJEVITA WILL BE AVAILABLE AT A DISCOUNTED MONTHLY PRICE OF $299

Source text: ID:nPn8Z45Pxa

Further company coverage: AMGN.O


((Reuters.Briefs@thomsonreuters.com;))

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.